First Ascent Biomedical is pioneering advancements in cancer treatment through its innovative Drug Prediction Platform, known as DxPP, which utilizes artificial intelligence (AI) and therapy-resistant cell technologies. This platform is designed to enhance treatment planning and drug development for cancer patients, particularly those who have exhausted standard therapies. By integrating causal machine learning with drug sensitivity testing, DxPP aims to accelerate the drug development pipeline across various cancer types. The platform is validated through collaborations with leading cancer centers and oncologists, providing a rapid turnaround for personalized treatment plans that are data-driven and tailored to individual patient needs.

Additionally, First Ascent Biomedical's xDRIVE platform represents a significant leap in medical oncology decision support systems. This first-in-kind technology combines functional drug testing, DNA/RNA sequencing, and AI-guided tumor weakness mapping to identify and prioritize therapeutic solutions based on a patient's unique tumor vulnerabilities. The xDRIVE platform has shown promising results, particularly in pediatric oncology, by offering personalized treatment options that improve survival rates and reduce the burden of treatment-related health issues. The company's commitment to addressing health disparities in cancer care is further exemplified by its recent grant from the Florida Cancer Innovation Fund, which aims to expand access to these advanced treatment options for underserved communities.

United States

For patients whose cancer has returned, First Ascent Biomedical provides new ways to fight by combining functional drug testing, genomics, and artificial intelligence to design an individualized treatment plan in a week for each patient. Our technology rapidly grows tumor bulk, more importantly chemo-resistant cells enabling the testing 100s of FDA-approved drugs to measure the cellular response of both cell populations. This is the key dataset for the AI engine, supported by genomics data to identify every cancer weakness and identify which drugs work.

First Ascent Biomedical

Company Details